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Iptakalim Preferentially Decreases Nicotine-induced Hyperlocomotion in Phen-
cyclidine-sensitized Rats: A Potential Dual Action against Nicotine Addiction and 
Psychosis
Nick Volf1, Gang Hu2, Ming Li1
1Department of Psychology, University of Nebraska-Lincoln, Lincoln, NE, USA, 2Jiangsu Key Laboratory of Neurodegeneration, Department 
of Pharmacology, Nanjing Medical University, Nanjing, China
Objective: Iptakalim is a putative ATP-sensitive potassium (KATP) channel opener. It is also a novel nicotinic acetylcholine re-
ceptor (nAChR) blocker and can antagonize nicotine-induced increase in dopamine release in the nucleus accumbens. Our 
recent work also shows that iptakalim exhibits a clozapine-like atypical antipsychotic profile, indicating that iptakalim may pos-
sess a dual action against nicotine addiction and schizophrenia.
Methods: The present study examined the potential therapeutic effects of iptakalim on nicotine use in schizophrenia. We created 
an animal model of comorbidity of nicotine addiction and schizophrenia by injecting male Sprague-Dawley rats with nicotine 
(0.40 mg/kg, subcutaneously［sc］) or saline, in combination with phencyclidine (PCP, 3.0 mg/kg, sc) or saline daily for 14 con-
secutive days. 
Results: During the PCP/nicotine sensitization phase, PCP and nicotine independently increased motor activity over time. PCP 
also disrupted prepulse inhibition (PPI) of acoustic startle response. Acute nicotine treatment attenuated the PCP-induced hyper-
locomotion and PCP-induced disruption of PPI, whereas repeated nicotine treatment potentiated these effects. Importantly, pre-
treatment with iptakalim (10-20 mg/kg, intraperitoneally) reduced nicotine-induced hyperlocomotion in a dose-dependent 
fashion. This reduction effect was highly selective: it was more effective in rats previously sensitized to the combination of PCP 
and nicotine, but less effective in rats sensitized to saline, nicotine alone or PCP alone. 
Conclusion: To the extent that the combined nicotine and PCP sensitization mimics comorbid nicotine addiction in schizophrenia, 
the preferential inhibitory effect of iptakalim on nicotine-induced hyperlocomotion suggests that iptakalim may be a potential 
useful drug for the treatment nicotine abuse in schizophrenia.
KEY WORDS: Iptakalim; Phencyclidine; Nicotine; Motor activity; Prepulse inhibition; Rats.
INTRODUCTION
Clinical observations suggest that there is a serious co-
morbidity of nicotine use and schizophrenia.1) Schizo-
phrenic patients also tend to be heavy smokers, defined as 
those who smoke more than one and a half packs a day. 2) 
They are also less likely to attempt quitting 3) and have a 
higher risk of developing smoking-related illnesses, such 
as lung cancer and cardiovascular disease.4) Thus, a drug 
that could reduce nicotine use while maintaining anti-
psychotic efficacy in the treatment of schizophrenia 
would be highly desirable. Unfortunately, all currently 
used antipsychotics except clozapine,5) are ineffective in 
this regard. Since clozapine use is limited because of its 
risk in causing life-threatening agranulocytosis, there is an 
urgent need to search and evaluate other effective pharma-
cological treatments with novel mechanisms of action. 
Iptakalim is a novel adenosine triphosphate (ATP)-sensi-
tive potassium (KATP) channel activator that was originally 
developed for the treatment of hypertension.6) It can pass 
easily through the blood-brain-barrier and shows a poten-
tial neuroprotective effect for neurons and astrocytes 
against ischaemia, trauma and neurotoxins.7,8) Iptakalim is 
also a novel nicotinic acetylcholine receptor (nAChR) 
blocker and is shown to antagonize nicotine-induced in-
crease in dopamine release in the nucleus accumbens.8,9) 
Our recent work shows that iptakalim also possesses a clo-
zapine-like antipsychotic activity.10) We found that iptaka-
lim is effective in reducing amphetamine- and phencycli-
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dine-induced hyperlocomotion as well as selectively dis-
rupting conditioned avoidance responding, three well-es-
tablished behavioral indices of antipsychotic activity.11,12) 
Similar to clozapine, iptakalim preferentially increases 
c-Fos expression in the medial prefrontal cortex, nucleus 
accumbens and lateral septum.10)
Based on these findings, we hypothesized that iptaka-
lim may be a drug with a dual action against nicotine 
use/abuse and psychosis. The objective of the present 
study was to provide a needed behavioral assessment of 
the potential therapeutic effects of iptakalim on nicotine 
use in schizophrenia using a preclinical animal approach. 
To establish an animal model of comorbidity of nicotine 
abuse in schizophrenia, we sensitized rats to phencycli-
dine (PCP, 3.0 mg/kg, subcutaneously [sc]), in combina-
tion with nicotine (0.4 mg/kg, sc) for 14 consecutive days. 
The PCP sensitization was chosen as a model of schizo-
phrenia because it mimics many aspects of the illness, 
such as hypoglutamatergic activity,13) prepulse inhibition 
(PPI) deficit,14) persistent deficits in cognition,15) social in-
teraction impairment,16) and increased depressive-like be-
havior during the forced swim test.17) The effects of re-
peated PCP and/or nicotine treatment, and their inter-
actions were assessed in a series of locomotor activity and 
PPI tests. The effects of iptakalim on nicotine-induced hy-
perlocomotion was taken as a measure of efficacy of ipta-
kalim to ameliorate the psychomotor stimulant and/or re-
warding effects of nicotine.18,19)
METHODS
Animals
Male Sprague-Dawley rats (226-260 g upon arrival; 
Charles River, Portage, MI, USA) were housed two per 
cage, in 48.3×26.7×20.3 cm transparent polycarbonate 
cages under 12-hour light/dark conditions (light on be-
tween 6:00 am and 6:00 pm). Room temperature was 
maintained at 22±1oC with a relative humidity of 45-60%. 
Food and water were available ad libitum. Animals were 
allowed at least one week of habituation to the animal fa-
cility before they were used in experiments. All proce-
dures were approved by the Institutional Animal Care and 
Use Committee at the University of Nebraska-Lincoln.
Motor Activity Monitoring Apparatus 
Each of the sixteen activity boxes (48.3×26.7×20.3 cm 
transparent polycarbonate cages) was equipped with a 
row of 6 photocell beams (7.8 cm between two adjacent 
photobeams) placed 3.2 cm above the floor of the cage. 
Motor activity was recorded as the number of the photo-
cell beam breaks by a custom-built program run on a 
computer. 
PPI of acoustic startle response apparatus
The PPI test was performed using six Startle Monitor 
Systems (Kinder Scientific, Julian, CA, USA) controlled 
by a computer. Each system was housed in a compact 
sound attenuation cabinet (35.56 cm wide×27.62 cm 
deep×49.53 cm high). A speaker (diameter: 11 cm) moun-
ted on the cabinet’s ceiling was used to generate acoustic 
stimuli (70 dB-120 dB). The startle response was meas-
ured by a piezoelectric sensing platform on the floor, 
which was calibrated daily. During testing, rats were 
placed in a rectangular box made of transparent Plexiglas 
(19 cm wide×9.8 cm deep×14.6 cm high) with an adjust-
able ceiling positioned atop the box, providing only lim-
ited restraint while prohibiting ambulation.
Drugs
Doses of nicotine hydrogen tartrate (Sigma, St. Louis, 
MO, USA) were expressed as free base dissolved in 0.9% 
saline. The nicotine solution was brought to a pH of 
7.0±0.2 with a dilute NaOH solution. We chose the 0.4 
mg/kg nicotine dose because it is a commonly used dose in 
a number of behavioral tasks, such as motor activity,20) con-
ditioned place preference,21,22) and working memory.23) 
The injection solutions of phencyclidine hydrochloride (a 
gift from NIDA Chemical Synthesis and Drug Supply 
Program) and iptakalim hydrochloride (IPT, 99.9%, a gift 
provided by the Institute of Pharmacology and Toxicol-
ogy, Academy of Military Medical Sciences of China to 
Dr. Hu) were obtained by mixing drugs with 0.9% saline. 
Nicotine and PCP were administered subcutaneously at a 
volume of 1.0 ml/kg. Iptakalim was administered intra-
peritoneally [ip], also at a volume of 1.0 ml/kg .10)
Experimental Procedure
1. Habituation and baseline PPI test (Days 1-2)
Sixty-four male Sprague-Dawley rats (2 batches of 32) 
were used. On the first day, all rats were habituated to both 
the locomotor activity (LMA) chambers and PPI cham-
bers for 30 minutes and 20 minutes respectively. On the 
second day, rats were habituated to the LMA chambers, 
followed by a baseline of PPI test. The PPI procedure was 
adapted from Culm and Hammer.24) Each session lasted 
approximately 18 minutes and began with a 5 minutes pe-
riod of 70 dB background noise (which continued throu-
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ghout the duration of the session) followed by four differ-
ent trial types: PULSE ALONE trials and three types of 
PREPULSE+PULSE trials, which consisted of a 20 mimi- 
seconds (ms) 73, 76, or 82 dB prepulse (3, 6, and 12 dB 
above background) followed 100 ms later by a 120 dB 
pulse. Each session was divided into 4 blocks. Blocks 1 
and 4 were identical, each consisting of 4 PULSE ALONE 
trials. Blocks 2 and 3 were also identical and each con-
sisted of 8 PULSE ALONE trials and 5 of each 
PREPULSE+PULSE trial type. A total of 54 trials were 
presented during each test session. Trials within each 
block were presented in a pseudorandom order and were 
separated by a variable intertrial interval averaging 15 sec-
onds (ranging from 9-21 seconds). Startle magnitude was 
defined as the maximum force (measured in Newtons) ap-
plied by the rat to the startle apparatus recorded over a pe-
riod of 100 ms beginning at the onset of the pulse stimulus. 
Startle responses from testing Blocks 2 and 3 were used to 
calculate percent PPI (%PPI) for each acoustic prepulse 
trial type: 
%PPI=100-
Average startle response to 
PREPULSE+PULSE trials
   ×100
Average statle response to 
PULSE ALONE trials
2. Sensitization induction by repeated PCP and/or 
nicotine treatment (Days 3-16)
After two days of habituation, the rats were randomly 
assigned to one of four groups (saline+saline [SAL+SAL], 
saline+nicotine [SAL+NIC], PCP+saline [PCP+SAL], and 
PCP+nicotine [PCP+NIC], n=16/group). Every day for 14 
days, the rats were brought into the lab in their home cages, 
allowed to habituate for 30 minutes, and then injected with 
either PCP (3.0 mg/kg, sc) or saline. This dose of PCP was 
chosen because it has been shown to produce a robust be-
havioral sensitization and disruption of learning.25-27) Five 
minutes later a second injection of either nicotine (0.4 
mg/kg, sc) or saline was administered. This sensitization 
phase lasted for 14 consecutive days. On Days 1, 6, 11 and 
13, the rats were also placed in the LMA chambers 4 mi-
nutes after the second injection. LMA was recorded for 90 
minutes. On Days 3, 8, 12 and 14, the rats were placed in 
the PPI chambers 5 minutes after the second injection and 
their PPI performance was tested. On days when rats were 
not tested, rats were injected in their home cages only.
3. PCP challenge test (Day 23) and iptakalim test on 
nicotine-induced hyperlocomotion in the same LMA 
boxes (Day 25)
Seven days after the last PCP/nicotine injections, all 
rats received a challenge dose of PCP (1.5 mg/kg, sc) and 
were tested in the LMA chambers to assess the PCP-in-
duced psychomotor sensitization for 90 minutes. Two 
days later, the effects of iptakalim treatment on nic-
otine-induced hyperlocomotion were assessed. Each of 
the original four groups was further divided into three sub-
groups: saline (n=8), iptakalim (10 mg/kg,   ip, n=4), or ip-
takalim (20 mg/kg, ip,  n=4). At the beginning of the test, 
rats were first injected with iptakalim or saline and 5 mi-
nutes later received a challenge dose of nicotine (0.2 
mg/kg, sc). Four minutes after receiving nicotine, rats 
were placed in the LMA chambers and motor activity was 
recorded for 90 minutes.
4. Iptakalim test on nicotine-induced hyperlocomotion in 
a novel environment (Day 29)
Four days after the first iptakalim test in the familiar 
LMA boxes, the effects of iptakalim treatment on nic-
otine-induced increase in motor activity were assessed in 
a novel environment to assess the generality of the iptaka-
lim effect on nicotine-induced hyperlocomotion. Rats 
were tested in 8 two-compartment chambers (64 cm 
wide×30 cm high×24 cm deep) housed in a ventilated, 
sound-insulated isolation cubicle (96.52 cm wide×35.56 
cm deep×63.5 cm high; Med Associates, St. Albans, VT, 
USA). The motor activity was detected by a set of 16 pho-
tobeams (ENV-256-8P; Med Associates, St. Albans, VT, 
USA) affixed at the bottom of the box (3.5 cm above the 
grid floor) as number of beam breaks. The groups were the 
same as in the first iptakalim test. At the beginning of the 
test, rats received the first injection of either saline, iptaka-
lim (10 mg/kg, ip), or iptakalim (20 mg/kg, ip), followed 
by a challenge dose of nicotine (0.2 mg/kg, sc) 5 minutes 
later. The motor activity test started immediately after the 
nicotine injection and lasted for 30 minutes.
Data Analysis
All data were expressed as mean+SEM. Motor activity 
from the PCP/nicotine sensitization induction phase were 
analyzed using repeated-measures analyses of variance 
(ANOVAs) with a within-subjects factor of test day and 
between-subjects factors of PCP and nicotine treatment. 
Percent PPI data at the three prepulse intensity levels (e.g., 
73, 76 and 82 dB) on the 4 drug testing days were pre-
sented separately and analyzed similarly with the ex-
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Fig. 1. Effects of repeated administration of SAL, PCP (3.0 mg/kg, 
sc), and NIC (0.4 mg/kg, sc) on locomotor activity (mean+SEM). 
A total of 64 rats were randomly assigned to one of four groups 
(n=16/group): SAL+SAL, SAL+NIC, PCP+SAL, and PCP+NIC and test-
ed on day 1, 6, 11 and 13 of drug treatment. *p＜0.05 significantly 
different from the SAL+SAL control group; †p＜0.05 significantly 
different between two PCP groups (NIC vs. SAL). SAL, saline; PCP, 
phencyclidine hydrochloride; NIC, nicotine; SEM, standard error of 
the mean.
ception that the prepulse level was added as a with-
in-subjects factor. One-way ANOVA followed by post 
hoc least significant difference (LSD) tests was used to de-
termine group differences on specific test days. Motor ac-
tivity data from the PCP challenge test were analyzed by 
a two-way ANOVA with PCP and nicotine as two be-
tween-subjects factors. Iptakalim data from the two nic-
otine challenge days were analyzed separately by a 
three-way ANOVA with iptakalim, PCP and nicotine as 
three between-subjects factors.
RESULTS
LMA during the Sensitization Induction Phase
Data for one rat in the SAL+SAL group on the last mo-
tor activity test was missing due to a technical error and 
were not entered in the analysis. As can be seen in Fig. 1, 
both PCP and nicotine treatment progressively increased 
motor activity throughout the four test days. Repeated 
measures ANOVA revealed a main effect of PCP, F(1, 
59)=332.68, p＜0.001, and nicotine, F(1, 59)=12.88, p= 
0.001, but no PCP×nicotine interaction, F(1, 59)=1.7879, 
p=0.187. Both PCP and nicotine also induced behavioral 
sensitization as evidenced by the significant PCP×test 
day, F(3, 177)=11.104, p＜0.001, and nicotine×test day 
interaction, F(3, 177)=16.980, p＜0.001. One-way ANOVA 
followed by the post hoc LSD tests on each test day showed 
that both PCP groups showed greater numbers of activity 
than the SAL+SAL group on all test days, p＜0.001. 
Nicotine treatment alone also significantly increased mo-
tor activity, as evidenced by the significant group differ-
ences between the SAL+NIC and SAL+SAL groups on 
the last three days of testing, p＜0.011. Interestingly, on 
the first day of testing, the PCP+NIC group had sig-
nificantly lower motor activity than the PCP+SAL group, 
p=0.034, suggesting an acute inhibitory effect of nicotine 
on PCP-induced hyperlocomotion. This effect was in con-
trast to the potentiated effect seen in the latter part of 
testing. The PCP+NIC group showed significantly higher 
motor activity than the PCP+SAL group on the last two 
testing days, p=0.009 and p＜0.001, respectively. 
PPI during the Sensitization Induction Phase
Data for two rats in the PCP+SAL group and two in the 
SAL+NIC groups were missing due to a technical error 
and were not analyzed. Fig. 2 shows PPI performance of 
the four groups of rats tested throughout the sensitization 
phase. PCP 3.0 mg/kg disrupted PPI at all three levels. 
Analysis of PPI data from the 4 drug test days revealed a 
main effect of PCP, F(1, 56)=120.647, p＜0.001, but no 
main effect of nicotine, F(1, 56)=1.821, p=0.183, nor 
PCP×nicotine interaction, F(1, 56)=0.086, p=0.770. The 
effect of prepulse level was significant, F(2, 112)=512.147, 
p＜0.001, but the effect of test day was not, F(3, 168)= 
2.085, p=0.104. There were also significant interactions be-
tween PCP×test day, F(3, 168)=3.012, p=0.032, PCP×pre-
pulse level, F(2, 112)=17.611, p＜0.001, and nicotine×test 
day, F(3, 168)=3.768, p=0.012, suggesting that the effects 
of PCP and nicotine on PPI performance varied across the 
test days.
At the 73 dB prepulse level, one-way ANOVA followed 
by post hoc LSD tests revealed that the two PCP groups 
had significantly lower PPIs than the two SAL groups on 
all test days, p＜0.031 except on the second PPI drug test 
day, the two PCP groups did not differ from the SAL+SAL 
group, p＞0.084. At the 76 dB prepulse level, once again, 
the two PCP groups had significantly lower PPIs than the 
other two groups on all test days, p＜0.012. Interestingly, 
the PCP+NIC group had even lower PPI on the last test 
day than the PCP+SAL group, p=0.041, suggesting that 
repeated nicotine treatment worsened the PPI-disruptive 
effect of PCP. At the 82 dB prepulse level, the two PCP 
groups also exhibited significantly lower PPIs than the 
two SAL groups, p＜0.002. In addition, on the first PPI 
drug test day, the PCP+NIC group had significantly high-
er PPI on than the PCP+SAL group, p=0.039. However, 
this effect was reversed on the second drug test day, 
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Fig. 2. Effects of repeated administration of SAL, PCP (3.0 mg/kg, 
sc), and NIC (0.4 mg/kg, sc) on PPI of acoustic startle response 
at the 73 dB prepulse level (A), 76 dB prepulse level (B) and 82 
dB prepulse level (C) (mean+SEM). A total of 64 rats were rando-
mly assigned to one of four groups (n=16/group): SAL+SAL, 
SAL+NIC, PCP+SAL, and PCP+NIC and tested on day 1, 6, 11 and 
13 of drug treatment. The PPI tests were conducted on the second 
habituation day (Hab), and on day 3, 8, 12 and 14 of drug treat-
ment. *p＜0.05 significantly different from the SAL+SAL control 
group; †p＜0.05 significantly different between two PCP groups 
(NIC vs. SAL). SAL, saline; PCP, phencyclidine; NIC, nicotine; PPI, 
prepulse inhibition; SEM, standard error of the mean.
Fig. 3. Effects of repeated administration of SAL, PCP (3.0 mg/kg, 
sc), and NIC (0.4 mg/kg, sc) on the expression of PCP locomotor 
sensitization during the PCP challenge test in the four groups of 
rats (n=16/group) that were previously treated with SAL+SAL, 
SAL+NIC, PCP+SAL, and PCP+NIC. Each rat was injected with PCP 
1.5 mg/kg, sc, and locomotor activity (mean+SEM) was recorded 
for 90 minutes. *p＜0.05 significantly different from the SAL+SAL 
control group. SAL, saline; PCP, phencyclidine; NIC, nicotine; SEM, 
standard error of the mean; SEM, standard error of the mean.
p=0.037. Inspection of the overall PPI patterns in the 
PCP+SAL and PCP+NIC groups across the four test days 
supports the observation that acute nicotine treatment 
tended to attenuate the PCP effect, while repeated treat-
ment tended to worsen it. This pattern of nicotine effect on 
PCP in the PPI model is consistent with its effect on 
PCP-induced hyperlocomotion.
PCP Sensitization Assessment
Fig. 3 shows motor activity in the four groups of rats 
challenged with PCP 1.5 mg/kg. Two-way ANOVA re-
vealed a main effect of PCP, F(1, 60)=12.242, p=0.001, 
confirming the PCP-induced behavioral sensitization. 
The nicotine effect was not significant, F(1, 60)=2.572, 
p=0.114, indicating that repeated nicotine treatment did 
not have a long-term impact on PCP sensitization. 
One-way ANOVA followed by post hoc LSD tested on the 
four groups showed that both PCP+SAL and PCP+NIC 
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groups showed significantly greater motor activity than 
the SAL+SAL group, p＜0.007.
Iptakalim test on nicotine-induced hyperlocomotion in 
the same LMA boxes
To examine the time course of the iptakalim effect on 
nicotine-induced increase in motor activity, we analyzed 
motor activity in each of 30 minutes blocks (a total of 3 
blocks) separately (Fig. 4). During the first 30 minutes of 
testing, three-way ANOVA revealed a main effect of nic-
otine, F(1, 52)=39.138, p＜0.001, suggesting that rats 
previously treated with nicotine expressed a nicotine be-
havioral sensitization. There was also a significant 
PCP×nicotine interaction, F(1, 52)=12.716, p=0.001, in-
dicating that the nicotine sensitization effect was modu-
lated by PCP sensitization. One-way ANOVA followed by 
post hoc LSD tests revealed that rats previously sensitized 
with SAL+NIC had significantly higher motor activity in 
comparison to the SAL+SAL/SAL group, p＜0.012. 
Iptakalim at both doses (10 and 20 mg/kg) did not de-
crease the nicotine-induced hyperlocomotion or the ex-
pression of nicotine sensitization. Rats previously sensi-
tized with PCP+NIC also showed significantly higher mo-
tor activity than the SAL+SAL/SAL rats when tested un-
der saline and iptakalim 20 mg/kg conditions, p＜0.006, 
but not under iptakalim 10 mg/kg condition, p=0.207, sug-
gesting that iptakalim 10 mg/kg reduced the nicotine-in-
duced hyperlocomotion to some extent. This observation 
was also supported by the finding that the PCP+NIC/IPT 
10 group exhibited significantly lower motor activity than 
the PCP+NIC/SAL group, p=0.045. In addition, rats pre-
viously sensitized with PCP+SAL showed significantly 
higher motor activity than the SAL+SAL/SAL rats, 
p=0.009 when they were tested under saline condition, in-
dicating a possible cross-sensitization from PCP to 
nicotine. This significant effect disappeared under iptakalim 
10 and 20 mg/kg conditions, p＞0.236. The overall pattern 
of the results indicates that iptakalim was more effective 
in decreasing nicotine-induced increase in motor activity 
in PCP sensitized rats than saline rats.
During the second 30 minutes of testing, there was still 
a main effect of nicotine, F(1, 52)=15.821, p＜0.001, a 
main effect of PCP, F(1, 52)=6.957, p=0.011, and a si-
gnificant PCP×nicotine interaction, F(1, 52)=8.568, 
p=0.005. One-way ANOVA followed by post hoc LSD 
tests revealed that only rats previously sensitized with 
SAL+NIC showed significantly higher motor activity in 
comparison to the SAL+SAL/SAL group, p＜0.011. 
Comparing each of the three subgroups sensitized to 
SAL+NIC to the corresponding subgroups sensitized to 
PCP+NIC revealed a significant between-group difference 
under the saline and iptakalim 10 test conditions, p＜0.021, 
suggesting that co-administration of PCP with nicotine at-
tenuated the nicotine sensitization effect during this test 
period. 
In the last 30 minutes, three-way ANOVA revealed a 
main effect of nicotine, F(1, 52)=11.258, p=0.001, a 
significant PCP×nicotine interaction, F(1, 52)= 6.645, 
p=0.013, and iptakalim×nicotine interaction, F(2, 
52)=5.634, p=0.006. Group comparisons revealed that in 
comparison to the SAL+SAL/SAL group, rats previously 
sensitized with SAL+NIC showed significantly higher 
motor activity when tested under saline and iptakalim 20 
mg/kg conditions, p＜0.041. Interestingly, iptakalim 20 
mg/kg potentiated nicotine-induced hyperlocomotion in 
rats previously sensitized to PCP+NIC. Rats in the 
PCP+NIC/IPT20 group showed significantly higher mo-
tor activity than the rats in the SAL+SAL/SAL group, 
p=0.030. They also had significantly higher activity than 
those sensitized to PCP+NIC but tested under saline or ip-
takalim 10 mg/kg,  p＜0.018.
Iptakalim Test on Nicotine-induced Hyperlocomotion in 
a Novel Environment
In this 30 minutes test, once again, iptakalim showed a 
selective inhibitory effect on nicotine-induced hyper-
locomotion in rats that were previously sensitized to 
PCP+NIC. It had little effect in rats previously sensitized 
to other combinations of drugs. Three-way ANOVA re-
vealed a main effect of nicotine, F(1, 52)=7.613, p=0.008, 
a significant PCP×nicotine interaction, F(1, 52)=8.020, 
p=0.007. The main effect of iptakalim was also sig-
nificant, F(2, 52)=5.041, p=0.010. Post hoc LSD tests in-
dicated that iptakalim 10 mg/kg differed significantly 
from saline, p=0.004; whereas iptakalim 20 mg/kg dif-
fered marginally from the saline, p=0.051. Group compar-
isons using one-way ANOVA followed by post hoc LSD 
tests revealed that in comparison to the SAL+SAL/SAL 
group, rats previously sensitized with SAL+NIC showed 
significantly higher motor activity when tested under sal-
ine and iptakalim 20 mg/kg conditions, p＜0.024. This 
significant group difference was abolished by iptakalim 
10 mg/kg, p=0.802. Rats previously sensitized with 
PCP+NIC also showed significantly higher motor activity 
than the SAL+SAL/SAL rats when tested under saline 
condition, p=0.029, but not under iptakalim 10 or 20 
mg/kg condition, p＞0.598, suggesting that iptakalim de-
creased the nicotine-induced increase in motor activity. 
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Fig. 4. Effects of iptakalim treatment (IPT; 0, 10 and 20 mg/kg, ip) on the expression of nicotine locomotor sensitization in the familiar 
environment during the nicotine challenge test in the four groups of rats (n=16/group) that were previously treated with SAL+SAL, SAL+NIC, 
PCP+SAL, and PCP+NIC. Each rat was injected with nicotine 0.2 mg/kg, sc and locomotor activity was recorded for 90 minutes. Locomotor 
activity (mean+SEM) was separated into (A) first 30 minutes, (B) second 30 minutes, and (C) last 30 minutes. *p＜0.05 significantly different 
from the SAL+SAL/SAL control group; †p＜0.05 significantly different between an iptakalim group and its SAL control; ‡p＜0.05 significantly 
different between one of the SAL+NIC groups and one of the PCP+NIC groups. SAL, saline; PCP, phencyclidine; NIC, nicotine; SEM, standard 
error of the mean.
 Iptakalim Effect on Nicotine 175
The inhibitory effect of iptakalim was confirmed by the
finding that the PCP+NIC/IPT 10 and PCP+NIC/IPT 20 
groups showed significantly lower motor activity than the 
PCP+NIC/SAL group, p＜0.029.
DISCUSSION
This present study investigated the potential ther-
apeutic effect of iptakalim on nicotine use in schizo-
phrenia. We created a rat model of comorbid nicotine ad-
diction in schizophrenia using a sensitization regimen in 
which rats were being repeatedly injected with a combina-
tion of nicotine (0.40 mg/kg, sc) and PCP (3.0 mg/kg, sc) 
for 14 consecutive days. We confirmed the nicotine and 
PCP sensitization during the induction phase (i.e., 14 days 
of repeated drug injection) as well as in the expression 
phase (i.e., in the challenge tests). Because behavioral 
sensitization induced by a drug of abuse is often thought to 
reflect the addictive potential of the drug,28) the con-
firmation of nicotine sensitization indicates that certain 
features of nicotine addiction had been successfully 
modeled. PCP sensitization is often regarded as a faithful 
model of schizophrenia.11,14,29,30) The demonstration of 
persistent PPI deficits induced by PCP sensitization sug-
gests that PCP-sensitized rats exhibited a schizophrenia- 
like cognitive deficit, as PPI deficit is one of hallmark fea-
tures associated with schizophrenia and is thought to con-
tribute to its various symptoms (e.g., sensory flooding and 
cognitive fragmentation).31,32) Overall, the 14-day sensiti-
zation regimen used in this study seems valid in capturing 
certain aspects of behavioral symptoms associated with 
nicotine use in schizophrenia. This allowed us to examine 
the effects of iptakalim on nicotine-induced hyper-
locomotion as a way to assess its therapeutic potential 
against nicotine addiction in schizophrenia. We found that 
pretreatment of iptakalim significantly and dose-depend-
ently reduced nicotine-induced hyperlocomotion. This ef-
fect lasted for approximately 30 minutes and was found in 
two distinct testing environments. The iptakalim’s attenu-
ation effect on nicotine-induced hyperlocomotion was al-
so selective as it was more effective in rats previously sen-
sitized to the combination of PCP and nicotine, but less ef-
fective in non-sensitized rats or those sensitized to nic-
otine alone or PCP alone. 
In the present study, we found two interesting inter-
actions between nicotine and PCP. Acute treatment of nic-
otine reduced PCP-induced hyperlocomotion and PCP- 
nduced disruption of PPI, whereas repeated treatment of 
nicotine potentiated both effects of PCP (Figs. 1, 2). 
Previous work on mice also found that acute nicotine 
ameliorates the PCP-induced deficit of PPI,33,34) and de-
creases PCP-induced hyperactivity35) in some strains of 
mice. This acute reversal effect of nicotine may be related 
to the well-documented acute motor suppressive effect of 
nicotine20,36,37) and is likely mediated by the reversal of the 
blocking effect of PCP on nAchRs.35) We are not aware of 
any work that has reported the potentiated effect of re-
peated nicotine treatment on repeated PCP-induced hy-
perlocomotion and PPI impairment. Result on the motor 
activity indicates a clear additive effect between these two 
drugs as they share a common psychomotor stimulation 
effect. The PPI result is not so easy to understand because 
nicotine alone did not significantly disrupt PPI (Fig. 2), 
and chronic nicotine treatment actually increases baseline 
PPI in Sprague-Dawley rats.38,39) Mechanistically, both 
nicotine and PCP have a common action in increasing ex-
tracellular dopamine release in the nucleus accumbens .40-43) 
Nicotine does so by stimulating nicotinic cholinergic re-
ceptors in the ventral tegmental area and the nucleus ac-
cumbens,44) and PCP does so by primarily blocking gluta-
matergic N-methyl-D-aspartate (NMDA) receptors .45-47) 
Thus repeated nicotine treatment may potentiate PCP-in-
duced hyperlocomotion by enhancing PCP-induced in-
crease in dopamine release in the nucleus accumbens.48) 
Alternatively, because both VTA and the nucleus ac-
cumbens receive direct glutamatergic input from the pre-
frontal cortex and action of PCP in this area has been im-
plicated in the regulation of its psychomotor effect,49) it is 
also possible that repeated nicotine potentiates PCP-in-
duced hyperlocomotion by enhancing PCP’s activity in 
the prefrontal cortex, e.g., potentiating PCP-induced in-
crease in glutamate release in the prefrontal cortex.13,50,51) 
In addition to increasing dopamine release in the pre-
frontal cortex,49,52) both nicotine and PCP also cause an 
excessive glutamate release in the prefrontal cortex50,51) 
and PCP’s noncompetitive antagonist actions on NMDA 
receptors and non-NMDA receptors are thought to medi-
ate its PPI-disruptive effect.14) Therefore, it is possible that 
the potentiated disruption of PCP-induced PPI deficit by 
repeated nicotine treatment is due to the additive effect of 
both drugs’ actions on the glutamate system in the pre-
frontal cortex.
The main finding of the present study was that iptaka-
lim dose-dependently reduced nicotine-induced hyperlo-
comotion. This finding is to some extent expected as evi-
dence from electrophysiological and microdialysis stud-
ies shows that iptakalim selectively inhibits α4β2- 
nAChRs,53) and antagonizes nicotine-induced increase in 
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Fig. 5. Effects of iptakalim treatment (IPT; 0, 10 and 20 mg/kg, ip) on the expression of nicotine locomotor sensitization in the novel 
environment during the nicotine challenge test in the four groups of rats (n=16/group) that were previously treated with SAL+SAL, SAL+NIC, 
PCP+SAL, and PCP+NIC. Each rat was injected with nicotine 0.2 mg/kg, sc and locomotor activity (mean+SEM) was recorded for 30 minutes 
in a new testing apparatus different from the one used in the inducton of NIC/PCP sensitization. *p＜0.05 significantly different from the 
SAL+SAL/SAL control group; †p＜0.05 significantly different between an iptakalim group and its saline control. SAL, saline; PCP, phencyclidine; 
NIC, nicotine.
dopamine release in the accumbens.9) Our finding pro-
vides additional behavioral support for iptakalim’s in-
hibitory action on nicotinic receptors. The novel finding is 
its preferential effect in PCP+NIC sensitized rats: iptaka-
lim was more efficacious in decreasing nicotine-induced 
increase in motor activity in PCP sensitized rats than in 
non-sensitized rats or rats sensitized to nicotine alone or 
PCP alone. During the first 30 minutes of testing in a fa-
miliar environment, iptakalim 10 mg/kg only significantly 
decreased nicotine-induced hyperlocomotion in rats pre-
viously sensitized to the combination of PCP and nicotine, 
but not in rats previously sensitized to saline, nicotine 
alone or PCP alone. The same pattern was found during 
the second test in a novel environment. Because nicotine 
challenge induced as much higher motor activity in rats 
sensitized to nicotine alone as in those sensitized to both 
nicotine and PCP (Figs. 4A, 5), the preferential effect of 
iptakalim could not be attributed to different levels of mo-
tor response to nicotine challenge.
Because iptakalim is also effective in reducing PCP-in-
duced LMA,10) and attenuates excessive dopamine and 
glutamate release in the nucleus accumbens induced by 
nicotine and cocaine,9,54,55) this preferential action of ipta-
kalim may be mediated by its preferential action against 
excessive dopamine and glutamate release induced by 
nicotine. As discussed in our previous study,10) iptakalim 
might do so by opening the KATP channels (the putative tar-
get sites of iptakalim). Opening of KATP channels is known 
to result in hyperpolarization of the cell membrane and 
limitation of Ca2+ influx, blocking subsequent neurotoxic 
biochemical cascades56) and reducing neurotransmitter 
release.7) Alternatively, recent receptor binding tests in-
dicate that iptakalim may have an inhibitory action against 
sigma 2 and 1 receptors (with 97% and 81% inhibition 
rates as measured in the radioligand binding assays, 
thanks to National Institute of Mental Health Psychoac-
tive Drug Screening Program). Because both nicotine and 
PCP effects have been suggested to be mediated at least 
partially by sigma receptors,57-59) iptakalim may thus de-
crease nicotine-induced hyperlcomotion by inhibiting sig-
ma receptors, as well as antagonizing nicotinic receptors. 
In addition, iptakalim may also antagonize β1 adrenergic 
receptor (86% inhibition rate), μ opioid receptor (75% in-
hibition rate) as well as Δopioid receptor (67% inhibition 
rate). This multi-receptor binding profile of iptakalim may 
explain the unexpected result that iptakalim 20 mg/kg 
seems less effective than iptakalim 10 mg/kg in decreas-
ing nicotine-induced hyperlocmotion. We speculate that 
with the increase of dose, iptakalim may act on more types 
of receptors, raising the possibility of diluting its main ac-
tion against nicotine. Obviously, this possibility can be ad-
dressed in future studies using selective agonists again 
these potential targets of iptakalim.
We should point out several limitations with the present 
study. First, we only used the LMA model to identify the 
anti-nicotine property of iptakalim. Other models such as 
nicotine-induced conditioned place preference or intra-
venous nicotine self-administration should also be used. 
Second, we did not examine the molecular mechanisms 
responsible for iptakalim effects in this model. As men-
tioned above, iptakalim may target multiple receptors or 
molecules to achieve its inhibitory effect on nicotine. 
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Third, we have not compared iptakalim with other nic-
otinic receptor antagonists such as mecamylamine in this 
study, thus how it may differ from other drugs as pharma-
cotherapy for nicotine addiction remain to be determined. 
Finally, our chosen animal model could not capture many 
aspects of schizophrenia; therefore the clinical im-
plication of our findings awaits further investigation. 
Nevertheless, the present study provides important pre-
liminary evidence that iptakalim may possess a dual ac-
tion against nicotine and PCP. This property is extremely 
important given that managing substance abuse including 
nicotine addiction is suggested to be a key target of schizo-
phrenia treatment.60) If iptakalim’s therapeutic potentials 
are confirmed, it would contribute to broader under-
standing of the neuropathophysiology of co-morbidity of 
nicotine addiction in schizophrenia. 
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